As of 2025-12-31, the Intrinsic Value of Kalvista Pharmaceuticals Inc (KALV) is -10.84 USD. This KALV valuation is based on the model Peter Lynch Fair Value. With the current market price of 15.68 USD, the upside of Kalvista Pharmaceuticals Inc is -169.12%.
Based on its market price of 15.68 USD and our intrinsic valuation, Kalvista Pharmaceuticals Inc (KALV) is overvalued by 169.12%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -10.84 - -10.84 | -10.84 | -169.12% |
| P/E | (19.25) - (33.73) | (26.55) | -269.4% |
| DDM - Stable | (18.72) - (64.78) | (41.75) | -366.3% |
| DDM - Multi | (10.60) - (29.05) | (15.60) | -199.5% |
| Market Cap (mil) | 792.62 |
| Beta | 0.81 |
| Outstanding shares (mil) | 50.55 |
| Enterprise Value (mil) | 821.15 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.56% |
| Cost of Debt | 5.00% |
| WACC | 8.84% |